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Abstract: Regulation of enzymatic activity is vital to living organisms. 
Here, we report the development and the genetic optimization of an 
artificial zymogen requiring the action of a natural protease to 
upregulate its latent asymmetric transfer hydrogenase activity. 
Complex biochemical cascades, which are essential to sustain 
life, rely on tightly cross-regulated enzymatic processes. Several 
complementary mechanisms are used by the cell to achieve 
such exquisite regulation including: (i) tuning of their expression 
(e.g. transcription or translation), (ii) reversible chemical 
modification (e.g. phosphorylation), (iii) substrate or product 
inhibition, (iv) reversible binding of a small molecule distant from 
its active site (i.e. allosteric regulation), (v) selective proteolysis 
by a protease.[1–3] The latter strategy enables organisms to 
spatially and temporally control the activity of toxic enzymes that 
are expressed as pro-enzymes, also called zymogens. The 
unraveling of their catalytic activity requires the selective 
hydrolysis by a cognate protease to convert them into their 
corresponding active state. 
In recent years, artificial metalloenzymes (ArMs hereafter), 
which result from anchoring an organometallic catalyst within a 
macromolecular scaffold, have emerged as an attractive 
alternative to organometallic catalysts. Thanks to their genetic 
encoding, well defined second coordination sphere, and non-
natural organometallic cofactor, these hybrid catalysts combine 
attractive features of both homogeneous catalysts and 
enzymes.[4–8] Our group recently demonstrated that such ArMs 
improve the bio-compatibility of the organometallic cofactor, the 
protein host providing protection against deactivation, allowing 
their integration into cascades with natural enzymes.[10–12]  
In a biomimetic spirit, we surmised that the activity of an 
anchored catalyst precursor might be upregulated by the action 
of an external trigger, ideally a natural enzyme, at a remote 
position in the host protein. Such systems could form the basis 
of more elaborate cross-regulated enzyme cascades whereby 
the product of the ArM-catalyzed reaction inhibits the activating 
enzyme. 
Herein, we report the optimization of an artificial zymogen 
based on the biotin-streptavidin technology (Figure 1). 
 
Figure 1. Upregulation of an artificial metalloenzyme is achieved by 
proteolytic cleavage of a tripeptide. A) Structure of the biotinylated cofactor. 
B) The biotinylated cofactor is activated upon coordination of a tripeptide that 
is released from the C-terminus of an engineered streptavidin (Sav = 
streptavidin, only one monomer depicted for clarity; AA = aminoacid).   
Inspired by a publication by Whitesides, we and others 
exploit the biotin-streptavidin technology for the creation of 
ArMs.[13–18] In the context of upregulation, we hypothesized that 
a biotinylated Cp*M moiety (M = Rh (III), Ir(III)) might prove 
versatile as:  
(i) The [Cp*biotMCl2]2 precursor (or in combination with wild-type 
streptavidin, WT Sav hereafter) shows limited catalytic activity, 
both for C–H activation (M = Rh(III)) and for imine reduction (M = 
Rh(III) or Ir(III)).[19–21] (ii) Addition of a suitable ligand (e.g. 
amidoamines, derived from natural amino acids) leads to 
significant rate acceleration for the transfer hydrogenation of 
imines and ketones.[19–22] (iii) Embedding a Cp*Ir moiety within 
Sav shields the cofactor from inhibition by other proteins, 
enabling enzyme cascades.[10–12]   
In the context of ligand-accelerated catalysis,[23] Hilvert et 
al. screened a library of tripeptides to identify ligands that 
accelerate the [Cp*IrL3]-catalyzed transfer hydrogenation (L = 
Cl– or H2O). They identified glycine-glycine-phenylalanine (GGF 
hereafter) as the tripeptide yielding the most active complex in 
combination with [Cp*IrCl2]2.[19] The tripeptide is thought to 
coordinate in a bidentate fashion to the iridium via the nitrogen 
atoms of the first two residues (i.e. a primary amine and an 
amide).[19,22] Installing the tripeptide (AA1AA2AA3 hereafter) at the 
C-terminus of a protein impedes its coordination to the iridium by 
masking the primary amine as an amide. It may be possible to 
upregulate the ATHase activity (ATHase) of [Cp*biotIrL3] ⊂ Sav, 
by encoding a cleavable tripeptide at the C-terminus of Sav. In 
the presence of a site-specific protease, the tripeptide is cleaved, 
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yielding a primary amine with increased affinity towards the 
iridium cofactor. The resulting Sav-embedded pianostool 
complex [Cp*biotIr(AA1AA2AA3)L] ⊂ Sav is may display enhanced 
ATHase compared to [Cp*biotIrL3] ⊂ Sav (Figure 1).  
Prior to engineering the zymogen, both the tripeptide and 
Sav can be optimized independently. For this purpose, a 
tripeptide AA1AA2AA3 library was combined with the zymogen 
consisting of [Cp*biotIrL3] ⊂ K121A Sav. This single point mutant 
was selected for initial screening as it was previously shown to 
afford superior ATHase activity compared to WT Sav.[10,20,24] The 
biotin-binding site/[Cp*biotIrL3]/AA1AA2AA3 ratio was set to 2 : 1 : 
2.2 to drive the equilibria towards formation of 
[Cp*biotIr(AA1AA2AA3)L] ⊂ K121A Sav.[25] To identify the best 
AA1AA2AA3 and Sav isoform combination, the following 
procedure was implemented (Figure 2): i) mix [Cp*biotIrCl2]2 and 
Sav in MOPS buffer (MOPS = 3-(N-morpholino)propanesulfonic 
acid); ii) incubate for 0.5 hours at 37 °C; iii) add the tripeptide 
AA1AA2AA3; iv) incubate for 12 hours; v) add sodium formate 
and substrate; vi) stir the reaction for 24 hours at 37 oC and vii) 
analyze the reaction mixture by HPLC. 
  
Figure 2. Asymmetric transfer hydrogenation of imines and ketones catalyzed 
by [Cp*biotIr(AA1AA2AA3)L] ⊂ Sav. Varying the streptavidin isoform and the 
tripeptide allows to optimize the performance of the artificial ATHase.  
Selected results, collected in Table 1, lead to the following 
conclusions:  
i) In the absence of the tripeptide, the biotinylated cofactor 
displays limited catalytic activity, both in the absence and in the 
presence of Sav (Table 1, entries 1, 2). 
ii) Addition of glycineamide or a di- or tripeptide leads to 
significant ATHase activity (Table S1, SI), confirming their 
ligand-accelerating effect on the ArMs.[19,20,22]  
iii) Although the activity of all peptide-iridium complexes 
[Cp*biotIr(AA1AA2AA3)L]  was reduced upon incorporation within 
Sav, the enantioselectivity significantly increased (Table S1, SI), 
highlighting the critical influence of the second coordination 
sphere around the iridium cofactor provided by Sav.  
iv) Although the GGF sequence reported by Hilvert performs 
very well in K121A (Table 1, Entry 3), the first amino acid of the 
AA1AA2AA3 sequence could be further fine-tuned (Table S1, SI). 
The SGF tripeptide proved superior in the presence of Sav 
K121A: up to 829 TON were obtained after 24 hours with imine 
1b, 1773 TON with imine 1a and 1431 TON with ketone 2 (Table 
1, Entry 4). For ketone 2, the addition of SGF to [Cp*biotIrL3] ⊂ 
K121A increases activity by a factor 49. Prolonging the reaction 
time leads to full conversion (i.e. 2000 TONs) with imine 1b 
within a week (Figure S2, SI), TONs > 3500 can be achieved 
with ketone 2 within 48 hours using 300 mM substrate, 
highlighting the robustness of the ArM.  
v) Next, Sav mutants were screened in the presence of SGF. As 
previously observed,[20,26] K121A outperformed WT Sav for 
transfer hydrogenation. Introduction of an additional mutation 
[Cp*biotIr(SGF)L] ⊂ S112A K121A Sav afforded 1956 and 1754 
TON  for imine 1a and ketone 2 respectively. Up to 57% ee (R)-
4 was obtained (Table 1, Entry 8). 
           Table 1. Selected results for the reduction of substrates 1a, 1b and 2 catalyzed by [Cp*biotIr(AA1AA2AA3)L] ⊂ Sava. 
       1a  1b  2 
Entry Sav mutant Ligand 
 
TON  ee (%) 
 
TON ee (%) 
 
TON  ee (%) 
1 - -  50 -   4 -   8 -  
2 K121A -  199 10 (R)  46 -   29 -  
3 K121A GGF  1151 10 (R)  444 41 (R)  734 33 (R) 
4 K121A SGF  1773 17 (R)  829 2 (R)  1431 38 (R) 
5 K121A YGF  1161 25 (R)  444 46 (R)  1014 31 (R) 
6 WT SGF  551 11 (S)  123 4 (R)  484 17 (R) 
7 K121E SGF  626 4 (R)  359 35 (R)  411 38 (S) 
8 S112A K121A SGF  1956 10 (R)  741 10 (S)  1754 57 (R) 
9 K121E YGF  888 21 (R)  457 73 (R)  290 7 (R) 
10 S112A K121A EGF  1406 7 (R)  231 81 (R)  449 24 (R) 
[a] Reactions were carried out at 37°C with 100 mM substrate, 50 µM [Cp*biotIr(AA1AA2AA3)L], 100 µM biotin binding sites of Sav mutant, 1.5 M sodium 
formate in 0.6 M MOPS buffer pH 7.8 (see Supporting Informations). All listed experiments were performed in triplicate: TON ± 10%, ee ± 1%; ee values are 
omitted for results with TON < 50). 
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vi) Taking advantage of this dual-component feature of the 
optimization scheme, we set out to improve the 
enantioselectivity by combining promising first and second 
coordination sphere components: [Cp*biotIr(YGF)L] ⊂ K121E Sav 
and [Cp*biotIr(EGF)L] ⊂ S112A K121A Sav afford (R)-3b in 73% 
ee and 81% ee respectively (Table 1 entries 9, 10).  
Having identified suitable combinations of Sav variants and 
tripeptides, the genetic encoding of Sav variants that include a 
protease cleavage site flanked by the tripeptide ligand was 
undertaken: Factor Xa was selected as the activating 
protease.[27] Correspondingly, its recognition site (e.g. IDGR\) 
followed by the XGF-activating peptide (X = S, Y) was 
genetically encoded at the C-terminus of Sav, starting at position 
A156. The C-terminal sequence of the mature Sav (A156-V-Q-
Q159)[28] was replaced by I156-D-G-R\S-G-F162 and I156-D-G-
R\Y-G-F162, for both K121A Sav (abbreviated K121A--SGF) 
and K121E Sav (K121E--YGF).  
UPLC-MS analysis revealed that both K121A--SGF and 
K121E--YGF are cleaved within a few hours by Factor Xa 
(Figure S1, SI). The following protocol was implemented: i) mix 
[Cp*biotIrCl2]2 and K121A--SGF (or K121E--YGF) in MOPS buffer, 
ii) add Factor Xa, iii) incubate 12 hours, iv) add formate and 
substrate, iv) stir for 24 hours at 37 °C and v) analyze by HPLC. 
Selected results illustrate the following features (Table 2): 
i) In the absence of Factor Xa, low conversion is observed, 
suggesting that the C-terminal tripeptide XGF (X = S, G) cannot 
bind the cofactor to activate the artificial zymogens [Cp*biotIrL3] ⊂ 
K121A--SGF and [Cp*biotIrL3] ⊂ K121E--YGF (Table 2, entries 1 
and 2). The background activity corresponds to that observed 
with [Cp*biotIrL3] ⊂ K121A Sav and [Cp*biotIrL3] ⊂ K121E Sav in 
the presence of Factor Xa and the absence of peptide (Table 2, 
entries 3 and 4). Together, these results suggest that the 
presence of the activating tripeptides at the C-terminus of Sav 
have no effect in the absence of Factor Xa, and the protease 
itself does not activate the cofactor by direct complexation.  
ii) Incubation with Factor Xa restores the ATHase activity and 
enantioselectivity of both zymogens (Table 2, entries 5 and 6). 
This confirms that the ArMs resulting from proteolytic cleavage 
are essentially identical to those obtained by combining the 
synthetic tripeptides with Sav mutants. This feature is 
reminiscent of natural zymogens. In contrast to [Cp*biotIrL3] ⊂ 
K121A--SGF, the ATHase derived from [Cp*biotIrL3] ⊂ K121E--
YGF is slower (up to ca. 25%) than its synthetic counterpart, 
possibly due to the slower cleavage by Factor Xa of K121E--
YGF compared to K121A--SGF (Figure S1, SI).  
In conclusion, an artificial zymogen with latent ATHase activity 
was designed and its upregulation by a natural enzyme 
demonstrated. Various creative strategies have been pursued in 
the past to engineer switchable homogeneous catalysts.[21,29,30] 
To the best of our knowledge, however, this constitutes the first 
report of an artificial zymogen upregulated by a natural protease. 
Both the host protein and the activating peptide ligand can be 
genetically encoded and orthogonally optimized to improve the 
catalytic activity and fine-tune enantioselectivity. This proof of 
concept presents a biocompatible strategy for the upregulation 
of an ArM, paving the way to implement and regulate 
bioorthogonal catalytic activity within a living organism. 
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